ATXI Avenue Therapeutics Inc
5,987
$3.86
$0.1393
(3.48%)
| Watchers | 5,987 |
| 52-Wk Low | $4.00 |
| 52-Wk High | $93.75 |
| Market Cap | $2.38M |
| Volume | 30,280.00 |
| 52-Wk High | $93.75 |
| 52-Wk Low | $4.00 |
Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Expands By 91.7%Zolmax • about 1 month ago
Avenue Therapeutics, Inc. (NASDAQ:ATXI - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 313,400...
Share to Feed
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization...
- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization...
BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of...
-In vivo data supports BAER-101's unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg ( GAERS ) model of absence epilepsy-MIAMI, Feb...
Avenue Therapeutics, Inc. (NASDAQ:ATXI Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest...
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Inc (NASDAQ: ATXI) shares are trading lower by 31% to $0.24 Friday morning after the company announced it has entered into warrant exercise agreements with existing read more...